Ascendis Pharma A/S (NASDAQ:ASND) Stock Rating Reaffirmed by Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report)'s stock had its "overweight" rating restated by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $173.00 target price on the biotechnology company's stock. Cantor Fitzgerald's target price would suggest a potential upside of 39.47% from the company's current price.

ASND has been the topic of several other reports. JPMorgan Chase & Co. increased their price target on shares of Ascendis Pharma A/S from $167.00 to $170.00 and gave the company an "overweight" rating in a research report on Friday, May 3rd. Wedbush increased their price target on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an "outperform" rating in a research report on Thursday, February 8th. Wells Fargo & Company increased their price target on shares of Ascendis Pharma A/S from $260.00 to $262.00 and gave the company an "overweight" rating in a research report on Friday, May 3rd. Morgan Stanley reiterated an "equal weight" rating and issued a $116.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, April 22nd. Finally, Citigroup upped their price objective on shares of Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a "buy" rating in a research note on Thursday, February 8th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $173.88.

Ascendis Pharma A/S Trading Down 0.6 %

Shares of NASDAQ:ASND traded down $0.78 during midday trading on Wednesday, hitting $124.04. 998,212 shares of the stock were exchanged, compared to its average volume of 380,775. The stock has a market cap of $7.22 billion, a P/E ratio of -12.99 and a beta of 0.54. Ascendis Pharma A/S has a twelve month low of $83.75 and a twelve month high of $161.00. The company has a 50 day moving average price of $144.04 and a 200-day moving average price of $130.25.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of large investors have recently bought and sold shares of ASND. GAMMA Investing LLC purchased a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at $25,000. Private Ocean LLC purchased a new position in shares of Ascendis Pharma A/S in the 1st quarter valued at $36,000. Quadrant Capital Group LLC raised its stake in shares of Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 151 shares during the period. EverSource Wealth Advisors LLC raised its stake in shares of Ascendis Pharma A/S by 37.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company's stock valued at $42,000 after acquiring an additional 91 shares during the period. Finally, Signaturefd LLC grew its holdings in Ascendis Pharma A/S by 31.9% during the 3rd quarter. Signaturefd LLC now owns 798 shares of the biotechnology company's stock valued at $75,000 after purchasing an additional 193 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.